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Abstract
Genotyping and molecular characterization of drug resistance
mechanisms in Mycobacterium leprae enables disease transmission
and drug resistance trends to be monitored. In the present study,
we performed genome-wide analysis of Airaku-3, a multi-
drug-resistant strain with an unknown mechanism of resistance
to rifampicin. We identiﬁed 12 unique non-synonymous sin-
gle-nucleotide polymorphisms (SNPs) including two in the trans-
porter-encoding ctpC and ctpI genes. In addition, two SNPs were
found that improve the resolution of SNP-based genotyping,
particularly for Venezuelan and South East Asian strains of
M. leprae.
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Introduction
Despite a massive decline in leprosy prevalence in the last
two decades, more than 200 000 new cases of leprosy are
recorded each year globally, indicating active transmission of
the infection [1]. Drug resistance to one or more anti-lep-
rosy drugs has been reported but is rare. As the causative
agent, Mycobacterium leprae, remains uncultivable, molecular
drug susceptibility testing offers a practical alternative. This
involves PCR-sequencing of the drug-resistance-determining
regions of the rpoB, folP1 and gyrA genes associated with
resistance to rifampicin, dapsone and oﬂoxacin, respectively
[2]. However, a previous study described low-levels of
rifampicin resistance in M. leprae Airaku-3, isolated from a
Japanese patient who relapsed after multidrug therapy [3].
This strain exhibited phenotypic resistance to rifampicin and
dapsone in a mouse footpad assay. Although the dap-
sone-resistance was attributable to the known folP1 muta-
tion (Thr53Ile), Airaku-3 has a wild-type rpoB sequence;
hence, an explanation for its rifampicin resistance is not
available [2].
Alternative mechanisms of rifampicin resistance have been
described in various bacterial species, for example, the rox gene
mediated mono-oxygenation of rifampicin [4] and duplication of
the rpoB gene as rpoB2 inNocardia [5]. There is no orthologue of
rox inMycobacterium tuberculosis andM. leprae. Over-expression
of RNA polymerase-binding protein A causes low level rifam-
picin resistance in Streptomyces coelicolor [6]. Its M. leprae
orthologue ML1439 and other relevant genes sigA (rpoT) and
sigEwere all found to be wild-type in our PCR-based analysis. As
per the M. leprae single nucleotide polymorphism (SNP) -geno-
typing scheme [7], Airaku-3 belongs to SNP subtype 1D,which is
the predominant genotype in many countries like Bangladesh,
India,Nepal, Madagascar,Malawi and the FrenchWest Indies [7–
9] and has a signiﬁcant representation in Japan [7], Yemen,
Venezuela [10] and the USA [11]. However, the genome of only
one strain (S11-Inde2 from India) of this subtype has been
sequenced [12]. Therefore, the Airaku-3 strain was selected for
genome-wide sequencing using the Illumina platform to inves-
tigate the genetic basis for resistance to rifampicin and to
improve the resolution of the existing SNP-genotyping scheme
for M. leprae.
In our present study, a bacillary suspension containing
c.10E+08 cells of M. leprae Airaku-3 [2] in 0.1 M NaOH was
passed through a 1-mL insulin syringe (0.30-mm needle) three
to ﬁve times, before DNA extraction [13]. Library preparation
was by the TruSeq ChipSeq method (Illumina). Paired-end
sequencing, with 101 cycles on a HiSeq2000 instrument
provided a total of 174.2 million reads of which 25% could
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be aligned with the M. leprae TN genome [14], yielding >1000
times coverage, using BOWTIE [15]. De novo assembly of these
reads was performed using VELVET [16] with k-mer size of 91.
SNPs were identiﬁed as described previously [7,12] by
comparison with the other M. leprae strains using PCR
sequencing or genome comparisons [7,11,12] to identify the
unique SNPs of the Airaku-3 genome (see Supporting infor-
mation, Tables S1, S2). The phylogenetic trees were obtained
with SPLITSTREE v.4.13.1 [17] using uncorrected p distances, the
Neighbour Joining method and 1000 times bootstrapping
(Fig. 1).
After de novo assembly of the reads the genome of M. leprae
Airaku-3 comprised 114 contigs (n50 = 42 Kb) covering
98.85% of the TN genome. All the gaps corresponded to
dispersed repeats. There was no evidence of structural
variations compared with the M. leprae TN reference genome,
thereby ruling out genome rearrangements or gene duplica-
tions as an explanation for rifampicin resistance in Airaku-3.
Upon comparing the genome sequence of Airaku-3 with the
M. leprae TN [14] reference genome, a total of 114 SNPs were
identiﬁed. Of these, 46 SNPs were not present in any other
M. leprae genomes. These included two non-synonymous
substitutions in genes with predicted transporter function
belonging to the P-type ATPase family: 888973C>T in gene
ctpC and 3209207G>A in ctpI. These two SNPs were also
absent in the remaining M. leprae strains (Table S2).
Airaku-3 shared 12 SNPs with the other SNP-type 1D strain
S11-Inde2 (Table S1). We analysed two of these SNPs
(953582C>T and 3262657C>T) in 24 strains belonging to
SNP subtype 1D from different countries (Table S2). SNP
3262657C>T correctly identiﬁed all of these 1D strains from
the remaining 42 strains of other genotypes. Furthermore, the
SNP 953582C>G distinguished the Venezuelan 1D strains
(n = 10) from the rest of the 1D strains originating from eight
different countries (Table S2). The 100 bp ﬂanking region of
this SNP in other mycobacterial outgroup species (M. tuber-
culosis complex, M. avium complex, M. kansassi, M. marinum
and M. ulcerans) revealed a ‘C’ at the corresponding base,
thereby deﬁning the ancestral base. Therefore, Venezuelan 1D
strains with a ‘C’ at position 953582 are designated as subtype
1D-1 while the remaining 1D strains with a derived base ‘G’
are termed 1D-2.
Though our present study does not reveal a clear expla-
nation for the rifampicin resistance phenotype of Airaku-3, it
has identiﬁed the unique SNPs, including two non-synonymous
SNPs in transporter genes, ctpC and ctpI. However, a functional
assay is required to determine whether either of these variant
genes/transporters confers any degree of rifampicin resistance.
Other transporters, for example, drrA (Rv2936), pstB (Rv0933)
[18] and Rv1258c [19] reportedly confer low-levels of
rifampicin resistance in M. tuberculosis. The Airaku-3 genome
revealed no mutations in its drrA (ML2352c) whereas the
orthologs of the remaining two genes (pstB and ML1104c) are
pseudogenes in M. leprae. Rifampicin-resistant M. tuberculosis
strains commonly possess compensatory mutations in the rpoC
gene that restore their ﬁtness [20]. This gene has a wild-type
sequence in Airaku-3.
The comparative genomics of 1D strains in this study has
discovered two useful markers: SNP3262657C>T deﬁnes the
1D genotype while the SNP953582C>G can further resolve
them into 1D-1 and 1D-2. We have also identiﬁed a
phylogeographic association of the 1D-1 genotype with
Venezuela. These markers can be useful for molecular
epidemiological studies in many countries where leprosy is
endemic and the 1D genotype is predominant, and can also
provide a possible explanation for disease acquisition in other
countries where sporadic cases are reported in the indigenous
population or among immigrants or citizens who have lived in
areas where leprosy is endemic. Previously, we had success-
fully resolved the subtype 3I strains into 3I-1 and 3I-2 using a
similar approach [11]. Hence, our present study further
FIG. 1. Phylogenetic relationship of Mycobacterium leprae Airaku-3
with other M. leprae genomes [12]. For phylogeny, only the genomic
positions in which all strains [12] had an unambiguous nucleotide call
(674 positions) were considered. Mycobacterium leprae Airaku-3 is
placed closest to another subtype 1D strain, S11-Inde2 from India,
both of which share 12 SNPs that were absent in any other SNP
genotypes. The geographic origins and the SNP genotypes are
indicated against each strain. The ancient strains from Europe are
indicated with a *. All bootstrap values are above 87 (average 99).
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exempliﬁes the value of genome-wide comparisons of a few
strains to uncover reliable phylogeographic markers that can
later be used for rapid PCR-based genotyping.
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